US Patent Issued to Arrowhead Pharmaceuticals on Sept. 8 for "RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use" (California, Wisconsin Inventors)

ALEXANDRIA, Va., Sept. 8 -- United States Patent no. 12,729,377, issued on Sept. 8, was assigned to Arrowhead Pharmaceuticals Inc. (Pasadena, Calif.).

"RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use" was invented by Zhen Li (San Diego), Rui Zhu (San Diego) and So Wong (Oregon, Wis.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, able to inhibit Angiopoietin-like 3 (also called ANGPTL3, ANGPL3, angiopoietin-like protein 3) gene expression, and compositions that include ANGPTL3 RNAi agents. Also disclosed are methods of use of ANGPTL3 RNAi agents and compositions. The AN...